Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 32, Number 8—August 2026

Research Letter

Antibodies Cross-Reactive with Bundibugyo Virus in Ferrets Vaccinated with Ebola Virus Vaccine

Jordan Wight, Helene Schulz, and Logan BanadygaComments to Author 
Author affiliation: Public Health Agency of Canada, Winnipeg, Manitoba, Canada (J. Wight, H. Schulz, L. Banadyga); University of Manitoba, Winnipeg (L. Banadyga)

Main Article

Figure 1

Detection of EBOV glycoprotein–, BDBV glycoprotein–, and SUDV glycoprotein–specific IgG in rVSV-EBOV– and rVSV-SUDV–vaccinated ferrets and controls in study of antibodies cross-reactive with BDBV in ferrets vaccinated with EBOV vaccine. Ferrets were vaccinated with 2 × 105 plaque-forming units of either rVSV-EBOV (A) or rVSV-SUDV (B). Control animals received saline only (C). On day 27 postvaccination, serum samples were collected. Serum was diluted 1:400 and assayed by indirect ELISA. Data shown are corrected absorbance levels calculated by subtracting the absorbance at 650 nm from the absorbance at 450 nm. BDBV, Bundibugyo virus; EBOV, Ebola virus; rVSV-EBOV, recombinant vesicular stomatitis virus–based vaccine encoding the Ebola virus glycoprotein; rVSV-SUDV, recombinant vesicular stomatitis virus–based vaccine encoding the Sudan virus glycoprotein.

Figure 1. Detection of EBOV glycoprotein–, BDBV glycoprotein–, and SUDV glycoprotein–specific IgG in rVSV-EBOV– and rVSV-SUDV–vaccinated ferrets and controls in study of antibodies cross-reactive with BDBV in ferrets vaccinated with EBOV vaccine. Ferrets were vaccinated with 2 × 105 plaque-forming units of either rVSV-EBOV (A) or rVSV-SUDV (B). Control animals received saline only (C). On day 27 postvaccination, serum samples were collected. Serum was diluted 1:400 and assayed by indirect ELISA. Data shown are corrected absorbance levels calculated by subtracting the absorbance at 650 nm from the absorbance at 450 nm. BDBV, Bundibugyo virus; EBOV, Ebola virus; rVSV-EBOV, recombinant vesicular stomatitis virus–based vaccine encoding the Ebola virus glycoprotein; rVSV-SUDV, recombinant vesicular stomatitis virus–based vaccine encoding the Sudan virus glycoprotein.

Main Article

Page created: June 11, 2026
Page updated: July 27, 2026
Page reviewed: July 27, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external